The Second Generation of BCR-ABL Tyrosine Kinase Inhibitors
- 158 Downloads
Imatinib was developed as the first molecularly targeted therapy to specifically inhibit the BCR-ABL kinase in Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML). Because of the excellent hematologic and cytogenetic responses, imatinib has moved toward first-line treatment for newly diagnosed CML. However, the emergence of resistance to imatinib remains a major problem in the treatment of Ph-positive leukemia. Several mechanisms of imatinib resistance have been identified, including BCR-ABL gene amplification that leads to overexpression of the BCR-ABL protein, point mutations in the BCR-ABL kinase domain that interfere with imatinib binding, and point mutations outside of the kinase domain that allosterically inhibit imatinib binding to BCR-ABL.The need for alternative or additional treatment for imatinib-resistant BCR-ABL-positive leukemia has guided the way to the design of a second generation of targeted therapies, which has resulted mainly in the development of novel small-molecule inhibitors such as AMN107, dasatinib, NS-187, and ON012380. The major goal of these efforts is to create new compounds that are more potent than imatinib and/or more effective against imatinib-resistant BCR-ABL clones. In this review, we discuss the next generation of BCR-ABL kinase inhibitors for overcoming imatinib resistance.
Key wordsBCR-ABL Tyrosine kinase inhibitor SRC Resistance
Unable to display preview. Download preview PDF.
- 29.Martinelli G, Martelli AM, Grafone T, et al. A new ABL kinase inhibitor (AMN107) has in vitro activity on CML Ph+ blast cells resistant to imatinib [abstract]. Blood. 2004;104:255b. Abstract 4687.Google Scholar
- 30.Giles F, Kantarjian H, Wassmann B, et al. A phase I/II study of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, on a continuous daily dosing schedule in adult patients (pts) with imatinib-resistant advanced phase chronic myeloid leukemia (CML) or relapsed/refractory Philadelphia chromosome (Ph+) acute lymphocytic leukemia (ALL) [abstract]. Blood. 2004;104:10a. Abstract 22.Google Scholar
- 34.Tokarski J, Newitt J, Lee FY, et al. The crystal structure of Abl kinase with BMS-354825, a dual SRC/ABL kinase inhibitor [abstract]. Blood. 2004;104:160a. Abstract 553.Google Scholar
- 36.Lee FY, Lombardo L, Camuso A, et al. BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad spectrum antitumor activities in vitro and in vivo [abstract]. Proc Am Assoc Cancer Res. 2005;46:159.Google Scholar
- 37.Sawyers CL, Shah NP, Kantarjian HM, et al. Hematologic and cyto-genetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC/ABL kinase inhibitor BMS-354825: results from a phase I dose escalating study [abstract]. Blood. 2004;104:4a. Abstract 1.CrossRefGoogle Scholar
- 38.Talpaz M, Kantarjian HM, Shah NP, et al. Hematologic and cyto-genetic responses in imatinib-resistant accelerated and blast phase chronic myeloid leukemia (CML) patients treated with the dual SRC/ABL kinase inhibitor BMS-354825: results from a phase I dose escalation study [abstract]. Blood. 2004;104:10a. Abstract 20.Google Scholar
- 41.Shah N, Sawyers CL, Kantarjian H, et al. Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinib-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL) [abstract]. J Clin Oncol. 2005;23:565s. Abstract 6521.CrossRefGoogle Scholar
- 50.Golas JM, Arndt K, Etienne C, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 2003;63:375–381.PubMedGoogle Scholar
- 53.Boschelli DH,Wu Z, Klutchko SR, et al. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors. J Med Chem. 1998;41:4365–4377.CrossRefPubMedGoogle Scholar